Human circulating CD24hi marginal zone B cells produce IgM targeting atherogenic antigens and confer protection from vascular disease

Tanyaporn Pattarabanjird,Anh Tram Nguyen,Chantel McSkimming,Huy Q Dinh,Melissa A Marshall,Yanal Ghosheh,Rishab Gulati,Chistopher Durant,Jenifer Vallejo,Ryosuke Saigusa,Fabrizio Drago,Thomas V Guy,Katherine Premo,Angela M Taylor,Soumen Paul,Bijoy Kundu,Stuart Berr,Ayelet Gonen,Sotirios Tsimikas,Yury Miller,Shiv Pillai,Klaus Ley,Catherine C Hedrick,Coleen A McNamara
DOI: https://doi.org/10.1038/s44161-023-00356-1
Abstract:IgMs that inactivate oxidation-specific epitopes (IgMOSE), which are secondary products of lipid peroxidization, protect against inflammatory diseases, including diet-induced atherosclerosis. However, the human B cell subtype that produces IgMOSE remains unknown. In this study, we used single-cell mass cytometry and adoptive transfer of B cell subtypes to NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice to identify B27+IgM+CD24hi cells as the major producers of IgMOSE in humans. Notably, these cells have characteristics of human circulatory marginal zone B (MZB) cells, which are known to be atheoroprotective IgM producers in mice. CD24 antibody treatment to reduce MZB cells and IgM in a hyperlipidemic humanized mouse model provides the evidence that MZB cells protect against vascular inflammation. Consistent with these findings, the frequency of B27+IgM+CD24hi cells (MZB) in patients inversely correlates with coronary artery disease severity.
What problem does this paper attempt to address?